Combination drug therapy for head and neck cancer that has spread
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck squamous cell carcinoma that has returned or spread and cannot be cured with surgery or radiation.
- Your cancer cells must have a specific protein called c-Met in at least 25% of the tumor sample.
- You have not had any previous systemic treatment (like chemotherapy or immunotherapy) for this recurrent or metastatic cancer.
- You are generally well enough to carry out daily activities (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You do not have a history of lung inflammation (interstitial lung disease or pneumonitis) that needed steroid treatment, and no active lung inflammation on a recent CT scan.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a combination of two drugs (nimotuzumab and adebrelimab) along with chemotherapy for people with head and neck cancer that has returned or spread, and who cannot take the standard chemo drug cisplatin. The goal is to see if this combination works and is safe for these patients.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.